-
Name:CEP-18770
Catalog No.:B0065
Structure:
Chemical Properties Cas No.:847499-27-8 Purity Limit: Synonyms: Molecular Weight:413.26 Formula:C21H28BN3O5 Storage: Solubility:
Shipping Condition
Quality Control & MSDS
Description Delanzomib, also known as CEP-18770, is An orally bioavailable synthetic P2 threonine boronic acid inhibitor of the chymotrypsin-like activity of the proteasome, with potential antineoplastic activity. Proteasome inhibitor CEP 18770 represses the proteasomal degradation of a variety of proteins, including inhibitory kappaBalpha (IkappaBalpha), resulting in the cytoplasmic sequestration of the transcription factor NF-kappaB; inhibition of NF-kappaB nuclear translocation and transcriptional up-regulation of a variety of cell growth-promoting factors; and apoptotic cell death in susceptible tumor cell populations. In vitro studies indicate that this agent exhibits a favorable cytotoxicity profile toward normal human epithelial cells, bone marrow progenitors, and bone marrow-derived stromal cells relative to the proteasome inhibitor bortezomib. The intracellular protein IkappaBalpha functions as a primary inhibitor of the proinflammatory transcription factor NF-kappaB
References Related products
- ER-805751
- PR-047
- TP-110
- Tyropeptin A
- Tyropeptin B
Tel: +86-411-39042497
sales@alphabiopham.com
Contact us now!
We'll offer you the best prices